Medicine Creek Analytics

A mostly new team at the DOH Medical Cannabis Program solicited feedback on potential revisions to rules on compliant products, testing, labeling, and logos.

With DOE staff moving forward on cannabis lab accreditation rulemaking, they explained the expected timeline for draft rules and heard feedback about the costly implications for labs.

After a background on the draft rulemaking and method list for cannabis laboratory standards, stakeholders raised a lot of concerns and questions around expense and implementation.

Members and agency staff provided praise and criticism of research articles put forward by staff involving “Regulatory Science,” cannabinoid differences, testing results, and terminology.

With the end of their legislative mandate weeks away, members searched for a path forward to advise on regulation of hemp consumables after a THC regulatory bill was signed into law.

Pausing emergency rulemaking which would lower action levels for some pesticides didn’t preclude public comments critical of the approach taken by agency staff to the overall situation.

Without guidance in defining ‘cannabinoid,’ consensus on its meaning or the scope of work for the group proved difficult, but agreement to prioritize regulatory issues emerged.

Committee members heard testimony in favor, opposed, and ‘other’ while seeking suggestions on THC levels for hemp products after the Senate decided any amount of THC was too much. 

At the first work group meeting, members introduced themselves and heard agency leaders’ intentions to gather input on the effectiveness of 2022 cannabis testing changes.

Leaders touched on several bills concerning cannabinoid regulation and “inactive” producer licenses in addition to a favorable court ruling and social equity program updates.